Spectral AI

MDAI

Market cap $53.2M

Overview Fund Activity

1.99 USD

+0.05

2.58%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

2.00

+0.01

0.5%

1 day

2.58%

5 days

5.85%

1 month

-5.69%

3 months

-3.4%

6 months

13.07%

Year to date

-27.11%

1 year

60.48%

5 years

-79.48%

10 years

-79.48%

About: Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Employees: 78

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

131% more capital invested

Capital invested by funds: $4.11M [Q1] → $9.49M (+$5.38M) [Q2]

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

4% more funds holding

Funds holding: 26 [Q1] → 27 (+1) [Q2]

0.76% more ownership

Funds ownership: 14.09% [Q1] → 14.85% (+0.76%) [Q2]

See Fund Rankings

Financial journalist opinion

DeepView® System highlighted at the European Burns Association Congress

DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the European Burns Association (EBA) conference, held from September 3rd – 6th in Berlin, Germany.

DeepView® System highlighted at the European Burns Association Congress

Spectral AI, Inc. (MDAI) Q2 2025 Earnings Call Transcript

Spectral AI, Inc. (NASDAQ:MDAI ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Dr.Michael DiMaio - Chairman of the Board Sara Prendergast - Corporate Participant Assistant General Counsel - Corporate Participant Vincent Stanley Capone - CFO, General Counsel & Corporate Secretary Conference Call Participants Carl Edward Byrnes - Northland Capital Markets, Research Division John D. Vandermosten - Zacks Small-Cap Research Ryan Benjamin Zimmerman - BTIG, LLC, Research Division Operator Good afternoon, everyone, and welcome to the Spectral AI Inc. Q2 2025 Financial Results Conference Call.

Spectral AI, Inc. (MDAI) Q2 2025 Earnings Call Transcript

Spectral AI Announces 2025 Second Quarter Financial Results

Q2 Overview Research & Development Revenue of $5.1 Million, total revenue for the first half of 2025 of $11.8 Million Strong Cash position of $10.5 Million Submission of De Novo application to FDA completed in Second Quarter of 2025 DALLAS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2025 and provided an update on its ongoing business activities. “We are pleased with the results of our second quarter of 2025 especially with our ability to complete our submission of our De Novo application earlier than projected to the US Food and Drug Administration (“FDA”).

Spectral AI Announces 2025 Second Quarter Financial Results

Spectral AI Schedules 2025 Second Quarter Financial Results and Conference Call

DALLAS, July 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System and focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 12, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day to discuss the results.

Spectral AI Schedules 2025 Second Quarter Financial Results and Conference Call

Spectral AI Announces Submission to FDA of its DeepView® System

DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and artificial intelligence (“AI”) algorithms to predict burn healing potential, today announced the submission of its De Novo 510k marketing clearance application to the FDA for the DeepView System, intended for use in burn care settings, including both burn centers and emergency departments. The De Novo regulatory pathway is being pursued due to the novel nature of this technology, which does not have a predicate device currently available in the U.S. market.

Spectral AI Announces Submission to FDA of its DeepView® System

DeepView® System highlighted at the annual British Burn Association conference

DALLAS, June 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the annual British Burn Association (BBA) conference, held from June 4th – 6th in Brighton, UK. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the globe.

DeepView® System highlighted at the annual British Burn Association conference

Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company's Chief Operating Officer (“COO”). Micek's promotion reflects his role change from Interim COO of the Company since May, 2024

Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer

Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders

DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company's total shares outstanding were represented at the meeting, either in person or by proxy.

Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders

Spectral AI, Inc. (MDAI) Q1 2025 Earnings Call Transcript

Spectral AI, Inc. (NASDAQ:MDAI ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Sara Prendergast - Assistant General Counsel Vincent Capone - CFO Conference Call Participants Ryan Zimmerman - BTIG Carl Byrnes - Northland Capital Markets John Vandermosten - Zacks Vadim Khalil - SP Angel Operator Good day, and welcome to the Spectral AI, Inc. First Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note that this event is being recorded.

Spectral AI, Inc. (MDAI) Q1 2025 Earnings Call Transcript

Spectral AI Announces 2025 First Quarter Financial Results

Q1 Overview Research & Development Revenue of $6.7 Million Improved Capital Structure Reflected in Cash of $14.1 Million Continued work on planned De Novo submission to the FDA in the first half of 2025 DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its ongoing business activities. “During the first quarter we continued to execute against our strategic plan and are working hard towards our De Novo submission to the FDA by the end of the first half of 2025,” said Dr. J.

Spectral AI Announces 2025 First Quarter Financial Results

See News Rankings

Charts implemented using Lightweight Charts™